Predictive and Prognostic Value of TRIM58 Protein Expression in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy.
Predictive and Prognostic Value of TRIM58 Protein Expression in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy.
复制标题
TRIM58蛋白表达对接受新辅助化疗的乳腺癌患者的预测和预后价值
DOI：
10.2147/bctt.s387209
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
三方基序含蛋白(Trim)家族成员在肿瘤发生和化疗耐药中起着重要作用。在这项研究中，我们的目的是确定TRIM58蛋白的表达是否与患者对新辅助治疗(NAT)的反应和他们的生存结果有关。对深圳市第二人民医院NAT前活检的女性乳腺癌标本进行免疫组织化学染色。采用单因素和多因素Logistic回归分析TRIM58蛋白表达与病理完全应答(PCR)的关系。用COX比例风险模型计算调整后的危险比(HR)，可信区间为95%(95%CI)。使用Kaplan-Meier绘图仪数据库分析TRIM58的预后价值。在所有患者中，TRIM58高表达与肿瘤体积较小有关(n=58)。多因素分析显示，TRIM58低表达是PCR值升高的独立预测因素(优势比=0.06，95%可信区间0.005~0.741，P=0.028)。Kaplan-Meier Plotter数据集显示，TRIM58高表达组的5年总生存率低于低表达组(HR=1.34，95%CI为1.07~1.67，P=0.01)。通路分析揭示了TRIM58在化疗耐药中的潜在机制。我们的研究表明，TRIM58是乳腺癌新辅助化疗敏感性和长期临床结果的一个有前途的生物标记物。它还可能有助于确定候选应答者和确定治疗策略。
Tripartite motif-containing protein (TRIM) family members play crucial roles in carcinogenesis and chemotherapy resistance. In this study, we aimed to determine whether TRIM58 protein expression is related to patient responses to neoadjuvant therapy (NAT) and their survival outcome. Immunohistochemistry was performed on female breast cancer samples from biopsies before NAT in Shenzhen Second People’s Hospital. Univariate and multivariate logistic regression tests were used to analyze the association between TRIM58 protein expression and pathological complete response (pCR). The Cox proportional hazards model was used to calculate the adjusted hazard ratio (HR) with a 95% confidence interval (95% CI). The Kaplan–Meier plotter database was used to analyze the prognostic value of TRIM58. High TRIM58 expression was associated with small tumor size in all the patients (n = 58). Multivariate analysis suggested that low TRIM58 expression was an independent predictive factor for higher pCR (odds ratio = 0.06, 95% CI 0.005–0.741, P = 0.028). The Kaplan–Meier Plotter dataset suggested that the TRIM58 high-expression group showed a worse 5-year overall survival than the low-expression group (HR = 1.34, 95% CI 1.07–1.67, P = 0.01). Pathway analysis revealed the potential mechanisms of TRIM58 in chemoresistance. Our study suggests that TRIM58 is a promising biomarker for both neoadjuvant chemosensitivity and long-term clinical outcomes in breast cancer. It may also help to identify candidate responders and determine treatment strategies.